| Autor: |
Kyla F. Ortved, Larry Alward, Bobby Cowles, Renata Linardi, Dhvani Barot, Alex Usimaki, Joseph R. Fedie, Deb Amodie, Laurie R. Goodrich |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Frontiers in Veterinary Science, Vol 11 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2297-1769 |
| DOI: |
10.3389/fvets.2024.1335972 |
| Popis: |
IntroductionAlpha 2 macroglobulin (A2M), a multi-functional protein in the plasma protease inhibitor class, regulates proinflammatory cytokines and the clearance of chondrodestructive enzymes in cases of joint injury and osteoarthritis (OA). The purpose of this study was to compare A2M concentrations in equine plasma samples processed by three commercial devices developed for stall-side regenerative joint therapy.MethodsPlasma samples were obtained from healthy adult horses (N = 13). Mass spectrometry analysis was used to determine the concentration of protein analytes in each sample. Selected reaction monitoring measured a specific A2M peptide as a surrogate of the whole A2M protein. A2M concentrations produced by each test device were compared for two sample types: a pre-concentrate or platelet-poor (PP) component and a final component for use in the horse.ResultsThere was no significant difference (p > 0.05) in the geometric mean (GM) concentration of A2M in the final concentration samples produced by the Alpha2EQ® device (N horses = 13) and the single-centrifugation PP samples produced by the Pro-Stride® APS (autologous protein solution) device (N = 13) and the Restigen® PRP (platelet-rich plasma) device (N = 11). When A2M content in final concentration samples produced by each device was compared, the Pro-Stride APS and Restigen PRP samples had significantly greater GM A2M content (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
